

## Expression of the *hTERT* Gene Is Regulated at the Level of Transcriptional Initiation and Repressed by Mad1

Çagatay Günes, Serge Lichtsteiner, Alain P. Vasserot, and Christoph Englert<sup>1</sup>

Research Center Karlsruhe, Institute of Genetics, 76344 Eggenstein-Leopoldshafen, Germany [Ç. G., C. E.], and Geron Corporation, Menlo Park, California 94025 [S. L., A. P. V.]

### Abstract

Telomerase, an enzymatic activity responsible for the replication of chromosome end structures, is strongly upregulated in most human cancers. In contrast, most differentiated tissues are telomerase negative. The rate-limiting step for telomerase activity seems to be the expression of the catalytic subunit of the enzyme, encoded by the human telomerase reverse transcriptase (*hTERT*) gene. The precise mechanism of how *hTERT* is regulated has not been elucidated yet. We show here that the down-regulation of *hTERT* mRNA during 12-*O*-tetradecanoylphorbol-13-acetate-induced differentiation of human U937 cells is a consequence of a fast decrease in the rate of transcription rather than changes in its half-life. The only transcription factor that has so far been implicated in the regulation of *hTERT* expression is the c-Myc oncoprotein. Our analysis shows that another member of the *myc/max/mad* network, *mad1*, encoding a transcriptional repressor that is significantly increased by 12-*O*-tetradecanoylphorbol-13-acetate treatment, represses *hTERT* promoter-driven reporter gene activity in transient transfection assays. This effect is dependent on the NH<sub>2</sub> terminal domain of Mad1, which mediates the association with the transcriptional corepressor mSin3. Our findings suggest the involvement of an additional transcription factor in the regulation of *hTERT* expression and may provide a model for how *hTERT* activity is controlled during the differentiation process in human somatic tissues.

### Introduction

Telomerase is a ribonucleoprotein complex that is responsible for the complete replication of chromosomal ends. These end structures, named telomeres, serve as protective caps and consist of short tandemly repeated DNA sequences. In humans, this sequence is TTAGGG, and the average telomere length is 5–15 kb (1, 2). Upon each cell division the chromosomal ends shorten at a rate of ~50–200 bp (3). This molecular erosion sets a physical limit to the potential number of cell divisions and serves as a “mitotic clock” defining the lifespan of somatic cells. One mechanism to escape this limitation is the activation of telomerase. Because telomerase can reset the mitotic clock, it has been linked to the processes of tumorigenesis and aging.

To date, three components associated with telomerase activity in humans have been identified. The RNA component of telomerase is encoded by the *hTR* gene (Refs. 4 and 5; now called *hTER*) and functions as the template for elongation of the telomeric repeat units. *hTER* is constitutively expressed in all cells and is therefore not likely to be involved in the regulation of telomerase activity (6). The same is true for another protein that is associated with telomerase, the product of the *TPI1/TLPI* gene (now called *hTEPI*), which is also expressed ubiquitously (7, 8). Recently, the catalytic subunit of human

telomerase has been cloned and named *hTERT*<sup>2</sup> because it possesses the activity of an RNA-dependent DNA polymerase (9–11). Only hTER and hTERT are required for the reconstitution of telomerase activity *in vitro* and therefore represent the minimal catalytic core of telomerase in humans (12).

Transfection of telomerase-negative cells with an *hTERT* cDNA has demonstrated that *hTERT* expression is rate-limiting for telomerase activity (13–15). Moreover, cells that ectopically express *hTERT* overcome crisis and have an extended life span, supporting the causal relationship between the shortening of telomeres and cellular senescence (16, 17). Telomerase activity has been shown to be associated with proliferation (18, 19); therefore, it is not surprising that almost all immortal and cancer cells display significant telomerase activity and express *hTERT* (20, 21). These observations and the finding that the *myc* oncogene can activate *hTERT* expression (22–25) indicate that this gene may play a critical role in tumorigenesis.

While telomerase becomes activated during neoplastic transformation, telomerase activity decreases during differentiation processes, which are accompanied by loss of proliferative potential. This has been studied in embryonic stem cells that were differentiated by the removal of leukemia inhibitory factor from the culture medium and in F9 teratocarcinoma after retinoic acid-induced differentiation (26). Loss of telomerase activity upon differentiation was also demonstrated in K-562 human erythroid leukemia cells as well as in HL-60 human promyelocytic leukemia cells (26, 27). In the latter, telomerase down-regulation was demonstrated to be an early event of the differentiation process and not its consequence (28). Repression of telomerase activity was subsequently demonstrated to be associated with the down-regulation of *hTERT* expression upon differentiation of HL-60 cells with TPA (10, 29). It is, however, not yet clear at which level of gene expression this down-regulation occurs.

The only transcription factor that has thus far been implicated in the regulation of *hTERT* is encoded by the *c-myc* oncogene (22–25). The ability of c-Myc to function as a transcription factor has been shown to depend upon its dimerization with the protein Max (reviewed in Ref. 30). In addition to the formation of stable complexes with c-Myc, Max also heterodimerizes with proteins of the Mad(Mxi1) family (30–32). These Mad/Max complexes act in an antagonistic manner to c-Myc/Max-induced transactivation and result in potent repression of gene expression. How these additional members of the Myc/Max/Mad network affect *hTERT* expression has, however, not been studied yet.

We have used the differentiation of human hematopoietic U937 cells by phorbol ester as a model to study the regulation of *hTERT* expression. We demonstrate here that the half-life of the *hTERT* mRNA is not altered by TPA treatment. Nuclear run-off analysis shows that the down-regulation of *hTERT* is a consequence of a decrease in transcriptional initia-

Received 10/27/99; accepted 3/3/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom requests for reprints should be addressed, at Research Center Karlsruhe, Institute of Genetics, Hermann von Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany. Phone: 49-7247-823444; Fax: 49-7247-823354; E-mail: christoph.englert@itg.fzk.de.

<sup>2</sup> The abbreviations used are: hTERT, human telomerase reverse transcriptase; TPA, 12-*O*-tetradecanoylphorbol-13-acetate; TRAP, telomeric repeat amplification protocol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RA, retinoic acid; RT-PCR, reverse transcription-PCR; ODC, ornithine decarboxylase; FACS, fluorescence-activated cell sorter.

tion of the gene. Furthermore, the decrease in *hTERT* activity is not preceded by a down-regulation of the oncoprotein c-Myc but is paralleled by an increase in levels of *mad1*. In transient transfection assays, Mad1 was able to repress *hTERT* promoter activity, an effect that was dependent on an E-box consensus sequence. The repressive effect of Mad1 also required an intact NH<sub>2</sub> terminal domain, which mediates the interaction with the corepressor mSin3.

## Materials and Methods

**Cell Culture, Differentiation, and Immunoprecipitations.** U937 cells were obtained from the European Collection of Cell Cultures and were kept in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum. For differentiation, cells were seeded at a density of  $1 \times 10^5$ /ml and TPA (10 ng/ml in 0.1% DMSO) or retinoic acid ( $5 \times 10^{-6}$  M in ethanol) was added to the medium. The transcriptional inhibitor actinomycin D was used at 5  $\mu$ g/ml. Differentiation was assessed by expression of the monocytic markers CD11a and CD11c as well as CD4, which is expressed on immature U937 cells. Analysis was done using FACS assay with the respective monoclonal antibodies (PharMingen).

Metabolic labeling followed by high stringency immunoprecipitation was done as described (33). For the detection of Mad1, a polyclonal antiserum directed against the COOH terminus of human Mad1 was used (Santa Cruz Biotechnology).

**Constructs, Transfections, and Reporter Gene Assays.** Generation of the *hTERT* promoter constructs pGRN150 and pGRN261 has been described (22). pGRN176 has been generated by digestion of pGRN150 with *Pml*I and *Srf*I and subsequent religation. Construct pGRN316 contains nucleotides +1 to -246 from the *hTERT* genomic sequence, i.e., sequences immediately upstream of the ATG codon, and has the same 3' configuration as pGRN261 (cloned into the *Eco*RI site of pSEAP2-Basic).

U937 cells were transfected in six-well dishes using SuperFect (Qiagen) with 0.6  $\mu$ g of reporter plasmid, 1.2  $\mu$ g of expression plasmid, and 0.2  $\mu$ g of internal control plasmid (pGL3 Control; Promega). Reporter gene activity was determined by the SEAP reporter gene assay (Roche).

**RT-PCR Analysis and TRAP Assay.** First-strand cDNA synthesis was done using 2–5  $\mu$ g of total RNA with SuperScript reverse transcriptase (Life Technologies, Inc.) in the presence of 100 ng of oligo-dT<sub>15</sub> primers in a volume of 20  $\mu$ l. The cDNA was diluted 1:5 in water, and 5  $\mu$ l of the reverse transcriptase reaction was used for PCR analysis in a total volume of 50  $\mu$ l containing 0.2  $\mu$ M specific primers, 10% DMSO, 1.5 mM MgCl<sub>2</sub>, 0.2 mM deoxynucleotide triphosphates, and 1 unit of Taq polymerase (Life Technologies, Inc.). For radioactive PCR analysis, 2.5  $\mu$ Ci of [ $\alpha$ -<sup>32</sup>P]dCTP (3000 Ci/mmol; Amersham) was added to the reaction. Amplification products were analyzed on 5% nondenaturing polyacrylamide gels. PCR analysis (94°C, 30 s; 55°C, 30 s; and 72°C, 1 min) was done for 33 (*hTERT*), 30 (*hTEP1*), or 21 cycles (*GAPDH*). For radioactive PCR, the linear range of amplification was determined previously, and amplification was done for 25 cycles for *hTERT* and *hTEP1*.

The primers were *hTERT*-5' (TCTGGATTTCAGGTGAACAGCC) and *hTERT*-3' (GGGTGGCCATCAGTCCAGGATGG) for *hTERT*, *hTEP1*-5' (TCAAGCCAAACC-TGAATCTGAG) and *hTEP1*-3' (CCCGAGTGAATCTTTCTACGC) for *hTEP1*, as well as *GAPDH*-5' (ACCACAGTCCATGCATCAC) and *GAPDH*-3' (TCCACCACCCTGTTGCTGTA) for *GAPDH*.

To determine the enzymatic activity of telomerase in cell extracts, we used the TRAP as described (20) with the TRAPeze kit (Oncor) according to the recommendations of the supplier. Each sample contains the equivalent of  $1 \times 10^4$  cells.

**Nuclear Run-Off and Electrophoretic Mobility Shift Assays.** Nuclear run-off analysis was performed as described (34) with some modifications. For the isolation of nuclei from U937 cells,  $5 \times 10^7$  cells were used per time point. All procedures were carried out at 4°C. Cells were collected by centrifugation and washed twice in PBS. The cell pellet was loosened by careful vortexing, resuspended in 4 ml of lysis buffer [10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl<sub>2</sub>, and 0.5% (v/v) NP40] and incubated on ice for 5 min. Nuclei were pelleted by centrifugation at  $500 \times g$  for 5 min. The supernatant was used for the isolation of cytoplasmic RNA. The nuclei were resuspended in 4 ml of lysis buffer and again centrifuged. The pellet was resuspended in 200  $\mu$ l of glycerol storage buffer [50 mM Tris-HCl (pH 8.3), 40% (v/v) glycerol, 5 mM MgCl<sub>2</sub>, and 0.1 mM EDTA] and either used immediately for the run-off assay or frozen in liquid N<sub>2</sub>.

For the run-off assay, 200  $\mu$ l of nuclei were mixed with 200  $\mu$ l of reaction buffer [10 mM Tris-HCl (pH 8.0), 5 mM MgCl<sub>2</sub>, 300 mM KCl, 0.5 mM each of ATP, CTP, and GTP, and 100  $\mu$ Ci of [ $\alpha$ -<sup>32</sup>P]UTP (800 Ci/mmol; Amersham)] and incubated with shaking for 30 min at 30°C. Subsequently, DNA was digested by the addition of 20  $\mu$ l of DNase I (1 mg/ml; RNase free) and incubation for 15 min at 30°C. Isolation of RNA was done using the TRIzol reagent (Life Technologies, Inc.) following the recommendations of the manufacturer.

Hybridization was performed with  $1 \times 10^6$  cpm labeled RNA per sample using 5 ml of the Rapid-hyb buffer (Amersham) according to the manufacturer's recommendations. To enhance sensitivity, the hybridization was done overnight. To reduce background signals, filters were washed under stringent conditions: two times in  $2 \times$  SSC/0.1% SDS, two times in  $0.2 \times$  SSC/0.1% SDS, and two times in  $0.1 \times$  SSC/0.1% SDS for 25 min at 65°C. For each gene, 1  $\mu$ g of a specific fragment was immobilized on a nylon membrane: for *hTERT* and *GAPDH*, the 450-bp (position 3014–3464) or the 449-bp (position 586–1039) amplification products described above; for *c-fos*, a 1-kbp *Pst*I fragment; and for *c-jun*, a 1.4-kbp *Sma*I-*Hind*III fragment of the respective cDNAs was used.

Electrophoretic mobility shift assays were performed using a 26-bp oligonucleotide containing the consensus E-box (Santa Cruz Biotechnology) and nuclear extracts from U937 cells, which were prepared as described (35). Approximately 10 fmol of labeled oligonucleotide (25,000 cpm) were incubated with 3  $\mu$ g of nuclear extract in the presence of 1  $\mu$ g of poly(deoxyinosinic-deoxycytidylic acid) in  $1 \times$  binding buffer (36) for 20 min at room temperature. Subsequently, 3  $\mu$ g of a c-Myc-specific antibody (N-262; Santa Cruz Biotechnology) or of an E2F-1-specific antibody (as a control) were added to the mixture, and after 10 min at room temperature, binding was allowed to occur overnight on ice. Complexes were separated on 5% nondenaturing polyacrylamide gels that were run at 4°C.

**Northern Blot and Array Analysis.** For Northern analysis, 20  $\mu$ g of cytoplasmic RNA were immobilized on a filter and sequentially probed with specific fragments to detect the *c-myc* (2.4-kb) and *mad1* (3.8 and 6.5-kb) mRNA without stripping the filter. To analyze the expression of *mad1* in human tumors, the commercially available Matched Tumor/Normal Expression Array (Clontech) was used. Hybridization with a *mad1*-specific probe was done according to the manufacturer.

## Results and Discussion

**Down-Regulation of Telomerase Activity and *hTERT* Expression upon Differentiation of U937 Cells.** To study the regulation of telomerase activity as well as *hTERT* mRNA expression upon cellular differentiation, we have chosen the human myeloid leukemic U937 cell line. RA as well as phorbol esters such as TPA induce U937 cells to differentiate along the monocytic and macrophage-like pathway. These cells are thus very similar to HL-60 cells, where telomerase activity has been studied (10, 26, 37) but are much easier to transfect and are therefore advantageous for the present study. In the first set of experiments, we analyzed whether the *hTERT* gene as well as telomerase activity is regulated in a similar manner in U937 cells as it has been reported for HL-60 cells. We performed RT-PCR analysis with *hTERT*- and *hTEP1*-specific primers at various time points after induction of differentiation of U937 cells with RA or TPA. As demonstrated in Fig. 1a, differentiation of these cells leads to a down-regulation of *hTERT* mRNA after 5 h and to its complete disappearance after 24 h. In contrast, the expression of *hTEP1* was slightly increased after the addition of the differentiating agents, an observation that has been reported earlier for HL-60 cells (38). TRAP assays using extracts from differentiating U937 cells showed that the addition of RA or TPA leads to a decrease of telomerase activity (Fig. 1b), although with much slower kinetics when compared with the *hTERT* mRNA. After 24 h, a reduction of telomerase activity was visible, and after 72 h, all the activity had disappeared. These data confirm that expression of *hTERT* is the rate-limiting step for telomerase activity. To verify that the experimental conditions used here resulted in the differentiation of U937 cells, we have examined expression of the cell surface markers CD4 as well as CD11a and CD11c (Fig. 1c). Whereas expression of the monocytic antigens




Fig. 1. Down-regulation of *hTERT* mRNA level and telomerase activity upon RA and TPA treatment of U937 cells. *a*, RT-PCR analysis with primers specific for *hTERT*, *hTEP1*, and *GAPDH*. Exponentially growing cells were induced with either RA or TPA for the times indicated. *b*, TRAP assay using extracts from U937 cells that were treated identically to the cells used in *a*. The positive control (*pos. control*) and the internal control (*IC*, reveals the absence of PCR inhibitors) are provided by the manufacturer of the kit (TRAPeze kit). For the negative controls (*neg. control*), extracts from untreated cells were used. *M*, 100-bp marker. *c*, differentiation of U937 cells. Cells were induced by TPA, and surface antigen expression was measured by FACS analysis using specific antibodies.

CD11a and CD11c increased upon TPA treatment, CD4 surface expression, which is a hallmark for immature U937 cells, was lost rapidly. We conclude from these experiments that *hTERT* regulation in U937 cells is tightly controlled and that these cells therefore

provide a useful model for studying the regulation of the *hTERT* gene upon differentiation. For all of the subsequent experiments, only TPA was used as a differentiating agent.

**The Half-Life of the *hTERT* mRNA Is Not Altered by TPA.** The rapid down-regulation of *hTERT* mRNA after TPA stimulation could result from a short half-life of the *hTERT* message. To test this and to examine whether TPA-mediated changes in *hTERT* mRNA stability contribute to its rapid disappearance, we performed semiquantitative RT-PCR analysis using DNA from actinomycin D-treated cells. In the presence of actinomycin D, a significant decrease of the *hTERT* mRNA could be observed as early as 1 h after addition of the drug (Fig. 2). After 4 h, *hTERT* message had almost completely disappeared. This regulation was specific because *hTEP1* mRNA was affected to a much lesser extent by the inhibitor. Densitometric analysis revealed the half-life of *hTERT* in U937 cells to be ~50 min. The rate of decay of the *hTERT* mRNA was not affected by the addition of TPA, which suggests that the induction of differentiation did not change *hTERT* mRNA stability. The decrease of *hTERT* message induced by TPA was slower than that induced by actinomycin D alone or by both drugs, indicating that there is still residual transcription of the *hTERT* gene after 6 h of TPA treatment.

**The Rate of *hTERT* Transcription Is Decreased by TPA Treatment.** Because altered mRNA stability is not responsible for the down-regulation of the *hTERT* mRNA upon induction of differentiation, we analyzed the level of initiation of *hTERT* transcription upon TPA treatment. Before and at various time points after induction of




Fig. 2. Determination of the *hTERT* mRNA half-life. *top*, semiquantitative RT-PCR analysis. Exponentially growing U937 cells were treated with 10 ng/ml TPA (*T*), 5  $\mu$ g/ml actinomycin D (*ActD*), or with a combination of both (*T+D*) for the times indicated; total RNA was extracted, and RT-PCR analysis was performed with primers specific for *hTERT* and *hTEP1*. To stay within a linear amplification range, PCR was done for 25 cycles in the presence of radiolabeled dCTP. *bottom*, quantitation of the *hTERT* mRNA levels in the *top panel* using the program NIH Image 1.61. The signal of the uninduced sample was set to 100%.




Fig. 3. *hTERT* mRNA is regulated at the transcriptional level. *top*, nuclear run-off analysis using nuclei from U937 cells that were either untreated or treated with TPA for the times indicated. Radiolabeled RNA was used as a probe for filters with immobilized fragments specific for *hTERT*, *c-fos*, *c-jun*, and *GAPDH*. Filters were exposed for 7 days. *bottom*, quantitation of the signals from the run-off assay shown in the *top* panel. To calculate the relative amounts of newly transcribed RNAs, signals were quantitated using the program NIH Image 1.61. Signals from uninduced cells were set to 100%. The relative increase of the *hTERT* mRNA at the 4-h time point might be attributable to a suboptimal induction of the cells.

differentiation by the addition of TPA, nuclei were isolated, and nuclear run-off experiments were performed. As shown in Fig. 3, the level of transcription of *hTERT* started to decrease as early as 15 min and was significantly down-regulated after 8 h of induction. In contrast, *GAPDH* expression was only mildly altered by the addition of TPA. To verify the effect of TPA on gene expression, we have included the immediate early genes *c-fos* and *c-jun* in the experiment. The expected transient rise in the expression of both genes that can be observed after 15 min serves as a positive control. These results indicate that the down-regulation of *hTERT* mRNA upon differentiation of U937 cells is predominantly caused by a decrease of the transcriptional activity of the gene.

***hTERT* Down-Regulation Is Not Preceded by Loss of *c-myc* Activity.** The *c-myc* oncogene has been implicated in the regulation of the *hTERT* gene (22–25). Using reporter constructs harboring fragments of the *hTERT* promoter, we could confirm that the overexpression of *c-myc* leads to activation of the *hTERT* promoter in transient transfection assays in U937 cells (Fig. 4f). We then wanted to investigate the level of endogenous *c-myc* expression in response to TPA treatment in our cell system. Surprisingly, RT-PCR (data not shown) and Northern analysis did not reveal significant changes in *c-myc* mRNA, whereas *hTERT* levels decreased after addition of the drug (Fig. 4a). To analyze possible posttranscriptional effects, we examined the level of c-Myc protein. The amount of c-Myc that could be supershifted from complexes binding to an E-box-containing fragment slightly decreased after TPA addition (Fig. 4b). This decrease, however, was not complete, and there was still significant c-Myc activity when *hTERT* expression had already disappeared. This observation represents an exception to the general observation that

*c-myc* mRNA and protein levels are turned off in differentiating cells. A similar observation, however, has been made in a subline of U937 cells in which TPA treatment did not result in a decrease in *c-myc* levels (39). Moreover, a c-Myc target gene, ODC decreased rapidly, despite high levels of c-Myc, but the mechanism by which ODC expression was down-regulated remained undetermined. As in the case with ODC, our results imply that c-Myc is not the only determinant of *hTERT* activity in U937 cells.

**Mad1 Can Repress the *hTERT* Promoter.** Whereas *c-myc* and *max* mRNA levels (data not shown) remained constant after TPA treatment, the amount of *mad1* mRNA and protein increased dramatically after induction of differentiation (Fig. 4, a and b). This observation is in agreement with earlier reports (40) and prompted us to test the effect of Mad1 on the *hTERT* promoter. Overexpression of Mad1 in transient transfection assays in U937 cells resulted in a consistent and significant decrease of *hTERT* promoter activity (Fig. 4d). This repressive effect of Mad1 was dose dependent (Fig. 4e). The *hTERT* promoter contains two E-box consensus sites, one of which is located close to the translational initiation codon at position –29 to –34 (proximal E-box), whereas the second one is at position –238 to –243 with regard to the ATG (distal E-box; Fig. 4c; Ref. 22). The effect of Mad1 on the *hTERT* promoter was dependent on an intact proximal E-box. Deletion of this E-box led to reporter gene activity that was almost indistinguishable from a construct without an obvious E-box consensus. This observation was paralleled by the effect of c-Myc on the *hTERT* promoter, which was also mainly exerted via the evolutionarily conserved proximal E-box (Fig. 4f; Ref. 22). Thus, c-Myc and Mad1 exert their transcriptional effects via the same site in the *hTERT* promoter. A comparison of the c-Myc and Mad1 effects on the reporters pGRN261 and pGRN316 suggests that sequences upstream of both E-boxes appear to contribute to the repression of the *hTERT* promoter by Mad1 and its activation by c-Myc. Although there is no additional E-box in the 5' region of pGRN261, the reporter harbors several additional sequence elements that deviate by only 1 bp from the canonical CACGTG. Whether c-Myc/Max and/or Mad1/Max complexes bind to these sites, however, remains to be shown. To exclude competition between Mad1 and c-Myc as the basis for the observed effect, we have used a mutant form of Mad1. The Mad $\Delta$ N mutant (41) is devoid of the mSin interaction domain (SID) and is therefore not able to actively repress transcription. As can be seen in Fig. 4d, cotransfection of Mad $\Delta$ N does not lead to repression of the *hTERT* promoter constructs. In contrast, the mutant led to a consistent increase in reporter gene activity. This effect could be explained by the displacement of endogenous Mad1, which is expressed at a low level in undifferentiated cells (Fig. 4b, *bottom*), by the overexpressed mutant form. Thus, repression of the *hTERT* promoter by Mad1 involves an active repression mechanism rather than simple competition with c-Myc.

**Mad1 Expression Is Lost in Human Tumors.** To analyze the expression of *mad1* in human tumors, we have measured *mad1* mRNA levels in an arrayed panel of human tumor and the respective normal tissue (Fig. 5). In a number of tissues, *mad1* expression was too low to be analyzed; but in the particular case of colon cancers, as many as 91% (10 of 11) of the tumors showed decreased *mad1* mRNA levels. In the combined 29 samples of tumors from colon, lung, stomach, and rectum, *mad1* expression was lost or down-regulated in 69% (20 of 29) as compared with normal tissue from the same patient. Of note, several members of the Mad family have been discussed as tumor suppressors (42). On the basis of our observations, one can therefore speculate that the repression of the *hTERT* promoter by Mad1 limits the replicative potential of a cell and thereby contributes to the tumor suppressor phenotype.

In summary, we have demonstrated that the down-regulation of *hTERT* expression in differentiating U937 cells occurs at the level of transcriptional initiation. Furthermore we provide evidence that in






Fig. 5. *Mad1* is down-regulated in human tumors. For the analysis of *mad1* expression in human tumors, a matched array of normal (N) and tumor tissue (T) from different patients was analyzed with a *mad1*-specific probe. Because the expression level of *mad1* varies between different organs, only those tissues with significant *mad1* levels are shown.

addition to the c-Myc oncoprotein, the transcriptional repressor Mad1 regulates *hTERT* activity. To our knowledge, Mad1 is the first transcription factor identified that can repress the *hTERT* gene. This finding might also open up the possibility for novel therapeutic strategies with regard to telomerase inhibition. Finally, we think the cellular system used here is a useful model for the regulation of *hTERT* activity during the differentiation of somatic tissues.

### Acknowledgments

We thank Dirk Eick for the *c-myc* expression construct and Bernhard Lüscher for the *mad1*, *madΔN*, and *max* constructs and valuable advice. We also thank Falk Weih, Michael Pankratz, and Bernhard Lüscher for reading and improving the manuscript; Martin Hegen for help with the FACS analysis; Carsten Weiss and the members of our lab for helpful discussions and suggestions; and Birgit Besenbeck, Stephan Brodbeck, and Robert Adams for excellent technical support.

### References

- Allshire, R. C., Dempster, M., and Hastie, N. D. Human telomeres contain at least three types of G-rich repeat distributed non-randomly. *Nucleic Acids Res.*, **17**: 4611–4627, 1989.
- Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., Jones, M. D., Meyne, J., Ratliff, R. L., and Wu, J. R. A highly conserved repetitive DNA sequence, (TTAGGG)<sub>n</sub>, present at the telomeres of human chromosomes. *Proc. Natl. Acad. Sci. USA*, **85**: 6622–6626, 1988.
- Vaziri, H., Schachter, F., Uchida, I., Wei, L., Zhu, X., Effros, R., Cohen, D., and Harley, C. B. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. *Am. J. Hum. Genet.*, **52**: 661–667, 1993.
- Blasco, M. A., Funk, W., Villeponteau, B., and Greider, C. W. Functional characterization and developmental regulation of mouse telomerase RNA. *Science (Washington DC)*, **269**: 1267–1270, 1995.
- Feng, J., Funk, W. D., Wang, S. S., Weinrich, S. L., Avilion, A. A., Chiu, C. P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. The RNA component of human telomerase. *Science (Washington DC)*, **269**: 1236–1241, 1995.
- Avilion, A. A., Piatyszek, M. A., Gupta, J., Shay, J. W., Bacchetti, S., and Greider, C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. *Cancer Res.*, **56**: 645–650, 1996.
- Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Bass, M. B., Arruda, I., and Robinson, M. O. A mammalian telomerase-associated protein. *Science (Washington DC)*, **275**: 973–977, 1997.
- Nakayama, J., Saito, M., Nakamura, H., Matsuura, A., and Ishikawa, F. *TLP1*: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. *Cell*, **88**: 875–884, 1997.
- Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., and Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. *Science (Washington DC)*, **277**: 955–959, 1997.
- Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A., and Weinberg, R. A. *hEST2*, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell*, **90**: 785–795, 1997.
- Kilian, A., Bowtell, D. D., Abud, H. E., Hime, G. R., Venter, D. J., Keese, P. K., Duncan, E. L., Reddel, R. R., and Jefferson, R. A. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. *Hum. Mol. Genet.*, **6**: 2011–2019, 1997.
- Beattie, T. L., Zhou, W., Robinson, M. O., and Harrington, L. Reconstitution of human telomerase activity *in vitro*. *Curr. Biol.*, **8**: 177–180, 1998.
- Weinrich, S. L., Pruzan, R., Ma, L., Ouellette, M., Tesmer, V. M., Holt, S. E., Bodnar, A. G., Lichtsteiner, S., Kim, N. W., Trager, J. B., Taylor, R. D., Carlos, R., Andrews, W. H., Wright, W. E., Shay, J. W., Harley, C. B., and Morin, G. B. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. *Nat. Genet.*, **17**: 498–502, 1997.

- Nakayama, J., Tahara, H., Tahara, E., Saito, M., Ito, K., Nakamura, H., Nakanishi, T., Ide, T., and Ishikawa, F. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. *Nat. Genet.*, **18**: 65–68, 1998.
- Counter, C. M., Meyerson, M., Eaton, E. N., Ellisen, L. W., Caddle, S. D., Haber, D. A., and Weinberg, R. A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. *Oncogene*, **16**: 1217–1222, 1998.
- Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. *Science (Washington DC)*, **279**: 349–352, 1998.
- Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorf, P. M., Sedivy, J. M., and Weinberg, R. A. Dissociation among *in vitro* telomerase activity, telomere maintenance, and cellular immortalization. *Proc. Natl. Acad. Sci. USA*, **95**: 14723–14728, 1998.
- Belair, C. D., Yeager, T. R., Lopez, P. M., and Reznikoff, C. A. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. *Proc. Natl. Acad. Sci. USA*, **94**: 13677–13682, 1997.
- Lee, H. W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., II, Greider, C. W., and DePinho, R. A. Essential role of mouse telomerase in highly proliferative organs. *Nature (London)*, **392**: 569–574, 1998.
- Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. *Science (Washington DC)*, **266**: 2011–2015, 1994.
- Kolquist, K. A., Ellisen, L. W., Counter, C. M., Meyerson, M., Tan, L. K., Weinberg, R. A., Haber, D. A., and Gerald, W. L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. *Nat. Genet.*, **19**: 182–186, 1998.
- Greenberg, R. A., O'Hagan, R. C., Deng, H., Xiao, Q., Hann, S. R., Adams, R. R., Lichtsteiner, S., Chin, L., Morin, G. B., and DePinho, R. A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. *Oncogene*, **18**: 1219–1226, 1999.
- Greider, C. W. Telomerase activation. One step on the road to cancer? *Trends Genet.*, **15**: 109–112, 1999.
- Wang, J., Xie, L. Y., Allan, S., Beach, D., and Hannon, G. J. Myc activates telomerase. *Genes Dev.*, **12**: 1769–1774, 1998.
- Wu, K. J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., and Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. *Nat. Genet.*, **21**: 220–224, 1999.
- Sharma, H. W., Sokoloski, J. A., Perez, J. R., Maltese, J. Y., Sartorelli, A. C., Stein, C. A., Nichols, G., Khaled, Z., Telang, N. T., and Narayanan, R. Differentiation of immortal cells inhibits telomerase activity. *Proc. Natl. Acad. Sci. USA*, **92**: 12343–12346, 1995.
- Holt, S. E., Wright, W. E., and Shay, J. W. Regulation of telomerase activity in immortal cell lines. *Mol. Cell Biol.*, **16**: 2932–2939, 1996.
- Savovskiy, E., Yoshida, K., Ohtomo, T., Yamaguchi, Y., Akamatsu, K., Yamazaki, T., Yoshida, S., and Tsuchiya, M. Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. *Biochem. Biophys. Res. Commun.*, **226**: 329–334, 1996.
- Ramakrishnan, S., Eppenberger, U., Mueller, H., Shinkai, Y., and Narayanan, R. Expression profile of the putative catalytic subunit of the telomerase gene. *Cancer Res.*, **58**: 622–625, 1998.
- Schreiber-Agus, N., and DePinho, R. A. Repression by the Mad(Mxi1)-Sin3 complex. *Bioessays*, **20**: 808–818, 1998.
- Ayer, D. E., Kretzner, L., and Eisenman, R. N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. *Cell*, **72**: 211–222, 1993.
- Zervos, A. S., Gyuris, J., and Brent, R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. *Cell*, **72**: 223–232, 1993.
- Larsson, L. G., Bahram, F., Burkhardt, H., and Luscher, B. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells. *Oncogene*, **15**: 737–748, 1997.
- Greenberg, M. E., and Ziff, E. B. Stimulation of 3T3 cells induces transcription of the *c-fos* proto-oncogene. *Nature (London)*, **311**: 433–438, 1984.
- Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. *Nucleic Acids Res.*, **17**: 6419, 1989.
- Sommer, A., Bousset, K., Kremmer, E., Austen, M., and Luscher, B. Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators. *J. Biol. Chem.*, **273**: 6632–6642, 1998.
- Bestilny, L. J., Brown, C. B., Miura, Y., Robertson, L. D., and Riabowol, K. T. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. *Cancer Res.*, **56**: 3796–3802, 1996.
- Reichman, T. W., Albanell, J., Wang, X., Moore, M. A., and Studzinski, G. P. Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. *J. Cell. Biochem.*, **67**: 13–23, 1997.
- Ryan, K. M., and Birnie, G. D. Cell-cycle progression is not essential for c-Myc to block differentiation. *Oncogene*, **14**: 2835–2843, 1997.
- Ayer, D. E., and Eisenman, R. N. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. *Genes Dev.*, **7**: 2110–2119, 1993.
- Cerni, C., Bousset, K., Seelos, C., Burkhardt, H., Henriksson, M., and Luscher, B. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. *Oncogene*, **11**: 587–596, 1995.
- Henriksson, M., and Luscher, B. Proteins of the Myc network: essential regulators of cell growth and differentiation. *Adv. Cancer Res.*, **68**: 109–182, 1996.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Expression of the *hTERT* Gene Is Regulated at the Level of Transcriptional Initiation and Repressed by Mad1

Çagatay Günes, Serge Lichtsteiner, Alain P. Vasserot, et al.

*Cancer Res* 2000;60:2116-2121.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/60/8/2116>

**Cited articles** This article cites 42 articles, 17 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/60/8/2116.full#ref-list-1>

**Citing articles** This article has been cited by 38 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/60/8/2116.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/60/8/2116>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.